KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies

International Journal of Cancer

Volumn 137, Issue 2, 2015, Pages 251-261

  Carbone, Antonino ^a   De Paoli, Paolo ^a   Gloghini, Annunziata ^b   Vaccher, Emanuela ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Castleman disease; KSHV associated MCD; multicentric Castleman disease; multitarget treatment; viral IL 6

Indexed keywords

BLEOMYCIN; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GANCICLOVIR; INTERLEUKIN 10; INTERLEUKIN 6; PREDNISONE; PRODRUG; RITUXIMAB; THALIDOMIDE; TOCILIZUMAB; VALGANCICLOVIR; VINCRISTINE; ZIDOVUDINE; VIRUS PROTEIN;

ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CD8+ T LYMPHOCYTE; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; EPSTEIN BARR VIRUS INFECTION; HEMOPHAGOCYTIC SYNDROME; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOALBUMINEMIA; HYPONATREMIA; INCIDENCE; INFLAMMATION; KAPOSI SARCOMA; LONG TERM CARE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; NONHODGKIN LYMPHOMA; NONHUMAN; ORF21 GENE; ORF36 GENE; OVERALL SURVIVAL; PATHOGENESIS; PLASMA CELL DYSCRASIA; PLASMABLASTIC LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SEROPREVALENCE; SPLENOMEGALY; THROMBOCYTOPENIA; TUMOR MICROENVIRONMENT; VIRUS GENE; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; ANIMAL; EPSTEIN BARR VIRUS; GIANT LYMPH NODE HYPERPLASIA; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM; PHYSIOLOGY; SARCOMA, KAPOSI; VIROLOGY;

ANIMALS; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HIV; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERLEUKIN-6; SARCOMA, KAPOSI; VIRAL PROTEINS;

EID: 84929251384     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28923     Document Type: Review

References (114)

1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012; 100: 1-441.
2. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens - part B: biological agents. Lancet Oncol 2009; 10: 321-2.
3. Cronin DM, Warnke RA,. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009; 16: 236-46.
4. Bower M,. How I treat HIV-associated multicentric castleman disease. Blood 2010; 116: 4415-21.
5. Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric castleman's disease. J Clin Oncol 2011; 29: 2481-6.
6. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC, 2008.
7. Chen KT,. Multicentric castleman's disease and kaposi's sarcoma. Am J Surg Pathol 1984; 8: 287-93.
8. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996; 10: 61-7.
9. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of kaposi sarcoma-associated herpesvirus-related non-hodgkin lymphoma in patients with HIV infection and multicentric castleman disease. Blood 2002; 99: 2331-6.
10. Oksenhendler E,. HIV-associated multicentric castleman disease. Curr Opin HIV AIDS 2009; 4: 16-21.
11. da Silva SR, de Oliveira DE,. HIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignancies. Cancer Lett 2011; 305: 175-85.
12. Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric castleman's disease. Ann Oncol 2009; 20: 775-9.
13. Castleman B, Iverson L, Menendez,. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956; 9: 822-30.
14. Gaba AR, Stein RS, Sweet DL, et al. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978; 69: 86-90.
15. Dittmer DP, Damania B,. Kaposi sarcoma associated herpesvirus pathogenesis (KSHV) - an update. Curr Opin Virol 2013; 3: 238-44.
16. Uldrick TS, Polizzotto MN, Yarchoan R,. Recent advances in kaposi sarcoma herpesvirus-associated multicentric castleman disease. Curr Opin Oncol 2012; 24: 495-505.
17. Deeks SG, Tracy R, Douek DC,. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39: 633-45.
18. Zietz C, Bogner JR, Goebel FD, et al. An unusual cluster of cases of castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med 1999; 340: 1923-4.
19. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000; 96: 2069-73.
20. Mylona EE, Baraboutis IG, Lekakis LJ, et al. Multicentric castleman's disease in HIV infection: A systematic review of the literature. AIDS Rev 2008; 10: 25-35.
21. Reddy D, Mitsuyasu R,. HIV-associated multicentric castleman disease. Curr Opin Oncol 2011; 23: 475-81.
22. Uldrick TS, Wang V, O'Mahony D, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with kaposi sarcoma-associated herpesvirus and HIV but without multicentric castleman disease. Clin Infect Dis 2010; 51: 350-8.
23. Polizzotto MN, Uldrick TS, Hu D, et al. Clinical manifestations of kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol 2012; 3: 73.
24. Tamburro KM, Yang D, Poisson J, et al. Vironome of kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6A. Virology 2012; 433: 220-5.
25. Engels EA, Sinclair MD, Biggar RJ, et al. Latent class analysis of human herpesvirus 8 assay performance and infection prevalence in sub-saharan Africa and Malta. Int J Cancer 2000; 88: 1003-8.
26. Rezza G, Lennette ET, Giuliani M, et al. Prevalence and determinants of anti-lytic and anti-latent antibodies to human herpesvirus-8 among Italian individuals at risk of sexually and parenterally transmitted infections. Int J Cancer 1998; 77: 361-5.
27. Qu L, Jenkins F, Triulzi DJ,. Human herpesvirus 8 genomes and seroprevalence in united states blood donors. Transfusion 2010; 50: 1050-6.
28. Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIV-associated multicentric castleman disease with ganciclovir treatment. Blood 2004; 103: 1632-4.
29. Shebl FM, Dollard SC, Pfeiffer RM, et al. Human herpesvirus 8 seropositivity among sexually active adults in uganda. PLoS One 2011; 6: e21286.
30. Del Mistro A, Baboci L, Frayle-Salamanca H, et al. Oral human papillomavirus and human herpesvirus-8 infections among human immunodeficiency virus type 1-infected men and women in italy. Sex Transm Dis 2012; 39: 894-8.
31. Reinheimer C, Allwinn R, Sturmer M,. Do fewer cases of kaposi's sarcoma in HIV-infected patients reflect a decrease in HHV8 seroprevalence? Med Microbiol Immunol 2011; 200: 161-4.
32. Seaberg EC, Wiley D, Martinez-Maza O, et al. Cancer incidence in the multicenter AIDS cohort study before and during the HAART era: 1984 to 2007. Cancer 2010; 116: 5507-16.
33. De Paoli P,. Novel virally targeted therapies of EBV-associated tumors. Curr Cancer Drug Targets 2008; 8: 591-6.
34. Murray PG, Deacon E, Young LS, et al. Localization of epstein-barr virus in castleman's disease by in situ hybridization and immunohistochemistry. Hematol Pathol 1995; 9: 17-26.
35. Seliem RM, Griffith RC, Harris NL, et al. HHV-8+, EBV+ multicentric plasmablastic microlymphoma in an HIV+ man: the spectrum of HHV-8+ lymphoproliferative disorders expands. Am J Surg Pathol 2007; 31: 1439-45.
36. Chen CH, Liu HC, Hung TT, et al. Possible roles of epstein-barr virus in castleman disease. J Cardiothorac Surg 2009; 4: 31, 8090-4-31.
37. Romani B, Engelbrecht S, Glashoff RH,. Functions of tat: the versatile protein of human immunodeficiency virus type 1. J Gen Virol 2010; 91: 1-12.
38. Zeng Y, Zhang X, Huang Z, et al. Intracellular tat of human immunodeficiency virus type 1 activates lytic cycle replication of kaposi's sarcoma-associated herpesvirus: role of JAK/STAT signaling. J Virol 2007; 81: 2401-17.
39. Chadburn A, Hyjek EM, Tam W, et al. Immunophenotypic analysis of the kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric castleman disease (MCD). Histopathology 2008; 53: 513-24.
40. Scala G, Ruocco MR, Ambrosino C, et al. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med 1994; 179: 961-71.
41. Fiorentini S, Marini E, Caracciolo S, et al. Functions of the HIV-1 matrix protein p17. New Microbiol 2006; 29: 1-10.
42. Giagulli C, Marsico S, Magiera AK, et al. Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS One 2011; 6: e17831.
43. Hyun TS, Subramanian C, Cotter MA, II, et al. Latency-associated nuclear antigen encoded by kaposi's sarcoma-associated herpesvirus interacts with tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells. J Virol 2001; 75: 8761-71.
44. Huang LM, Chao MF, Chen MY, et al. Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1. J Biol Chem 2001; 276: 13427-32.
45. Giffin L, Damania B,. KSHV: pathways to tumorigenesis and persistent infection. Adv Virus Res 2014; 88: 111-59.
46. Guihot A, Oksenhendler E, Galicier L, et al. Multicentric castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+ T cells. Blood 2008; 111: 1387-95.
47. Guihot A, Dupin N, Marcelin AG, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic kaposi sarcoma. J Infect Dis 2006; 194: 1078-88.
48. Sabbah S, Jagne YJ, Zuo J, et al. T-cell immunity to kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells. Blood 2012; 119: 2083-92.
49. Akkina R,. New generation humanized mice for virus research: comparative aspects and future prospects. Virology 2013; 435: 14-28.
50. Wong SW, Bergquam EP, Swanson RM, et al. Induction of B cell hyperplasia in simian immunodeficiency virus-infected rhesus macaques with the simian homologue of kaposi's sarcoma-associated herpesvirus. J Exp Med 1999; 190: 827-40.
51. Estep RD, Powers MF, Yen BK, et al. Construction of an infectious rhesus rhadinovirus bacterial artificial chromosome for the analysis of kaposi's sarcoma-associated herpesvirus-related disease development. J Virol 2007; 81: 2957-69.
52. Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, et al. HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric castleman disease in mice. Blood 2012; 119: 5173-81.
53. Ballon G, Chen K, Perez R, et al. Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice. J Clin Invest 2011; 121: 1141-53.
54. Liapis K, Clear A, Owen A, et al. The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood 2013; 122: 424-33.
55. Dossier A, Meignin V, Fieschi C, et al. Human herpesvirus 8-related castleman disease in the absence of HIV infection. Clin Infect Dis 2013; 56: 833-42.
56. Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332: 1186-91.
57. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric castleman's disease. Blood 1995; 86: 1276-80.
58. Yarchoan R, Tosato G, Little RF,. Therapy insight: AIDS-related malignancies - the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol 2005; 2: 406, 415; quiz 423.
59. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000; 95: 1406-12.
60. Carbone A, Cesarman E, Spina M, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood 2009; 113: 1213-24.
61. Hassman LM, Ellison TJ, Kedes DH,. KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest 2011; 121: 752-68.
62. Amin HM, Medeiros LJ, Manning JT, et al. Dissolution of the lymphoid follicle is a feature of the HHV8+ variant of plasma cell castleman's disease. Am J Surg Pathol 2003; 27: 91-100.
63. Fend F, Cabecadas J, Gaulard P, et al. Early lesions in lymphoid neoplasia. J Hematopathol 2012; 5: 169-99.
64. Boshoff C, Weiss R,. AIDS-related malignancies. Nat Rev Cancer 2002; 2: 373-82.
65. Carroll PA, Brazeau E, Lagunoff M,. Kaposi's sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology 2004; 328: 7-18.
66. Hong YK, Foreman K, Shin JW, et al. Lymphatic reprogramming of blood vascular endothelium by kaposi sarcoma-associated herpesvirus. Nat Genet 2004; 36: 683-5.
67. Sivakumar R, Sharma-Walia N, Raghu H, et al. Kaposi's sarcoma-associated herpesvirus induces sustained levels of vascular endothelial growth factors A and C early during in vitro infection of human microvascular dermal endothelial cells: biological implications. J Virol 2008; 82: 1759-76.
68. Sakakibara S, Tosato G,. Regulation of angiogenesis in malignancies associated with epstein-barr virus and kaposi's sarcoma-associated herpes virus. Future Microbiol 2009; 4: 903-17.
69. Sakakibara S, Pise-Masison CA, Brady JN, et al. Gene regulation and functional alterations induced by kaposi's sarcoma-associated herpesvirus-encoded ORFK13/vFLIP in endothelial cells. J Virol 2009; 83: 2140-53.
70. Moore PS, Chang Y,. Molecular virology of kaposi's sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci 2001; 356: 499-516.
71. Klein U, Gloghini A, Gaidano G, et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 2003; 101: 4115-21.
72. Fan W, Bubman D, Chadburn A, et al. Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol 2005; 79: 1244-51.
73. Novak RM, Richardson JT, Buchacz K, et al. Immune reconstitution inflammatory syndrome: Incidence and implications for mortality. AIDS 2012; 26: 721-30.
74. Rajasuriar R, Khoury G, Kamarulzaman A, et al. Persistent immune activation in chronic HIV infection: Do any interventions work? AIDS 2013; 27: 1199-208.
75. Kowalkowski MA, Mims MP, Amiran ES, et al. Effect of immune reconstitution on the incidence of HIV-related hodgkin lymphoma. PLoS One 2013; 8: e77409.
76. Kishimoto T,. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22: 347-52.
77. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated kaposi's sarcoma. Science 1994; 266: 1865-9.
78. Moore PS, Boshoff C, Weiss RA, et al. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996; 274: 1739-44.
79. Aoki Y, Yarchoan R, Wyvill K, et al. Detection of viral interleukin-6 in kaposi sarcoma-associated herpesvirus-linked disorders. Blood 2001; 97: 2173-6.
80. Aoki Y, Tosato G, Fonville TW, et al. Serum viral interleukin-6 in AIDS-related multicentric castleman disease. Blood 2001; 97: 2526-7.
81. Meckes DG, Jr, Gunawardena HP, Dekroon RM, et al. Modulation of B-cell exosome proteins by gamma herpesvirus infection. Proc Natl Acad Sci USA 2013; 110: E2925-33.
82. Chugh PE, Sin SH, Ozgur S, et al. Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. PLoS Pathog 2013; 9: e1003484.
83. Stebbing J, Pantanowitz L, Dayyani F, et al. HIV-associated multicentric castleman's disease. Am J Hematol 2008; 83: 498-503.
84. Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for kaposi sarcoma herpesvirus-associated multicentric castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood 2011; 117: 6977-86.
85. Hoffmann C, Schmid H, Muller M, et al. Improved outcome with rituximab in patients with HIV-associated multicentric castleman disease. Blood 2011; 118: 3499-503.
86. Gerard L, Michot JM, Burcheri S, et al. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric castleman disease. Blood 2012; 119: 2228-33.
87. Bower M, Pria AD, Coyle C, et al. Diagnostic criteria schemes for multicentric castleman disease in 75 cases. J Acquir Immune Defic Syndr 2014; 65: e80-2.
88. Naresh KN, Rice AJ, Bower M,. Lymph nodes involved by multicentric castleman disease among HIV-positive individuals are often involved by kaposi sarcoma. Am J Surg Pathol 2008; 32: 1006-12.
89. Borie R, Cadranel J, Galicier L, et al. Pulmonary involvement due to HHV-8 virus during the course of HIV infection. Rev Mal Respir 2012; 29: 1209-23.
90. Stebbing J, Adams C, Sanitt A, et al. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric castleman disease. Blood 2011; 118: 271-5.
91. Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in kaposi sarcoma herpesvirus-associated multicentric castleman disease. Blood 2013; 122: 4189-98.
92. Dieval C, Bonnet F, Mauclere S, et al. Multicentric castleman disease: use of HHV8 viral load monitoring and positron emission tomography during follow-up. Leuk Lymphoma 2007; 48: 1881-3.
93. Barker R, Kazmi F, Stebbing J, et al. FDG-PET/CT imaging in the management of HIV-associated multicentric castleman's disease. Eur J Nucl Med Mol Imaging 2009; 36: 648-52.
94. Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric castleman's disease: ANRS 117 CastlemaB trial. J Clin Oncol 2007; 25: 3350-6.
95. Fardet L, Blum L, Kerob D, et al. Human herpesvirus 8-associated hemophagocytic lymphohistiocytosis in human immunodeficiency virus-infected patients. Clin Infect Dis 2003; 37: 285-91.
96. Stebbing J, Ngan S, Ibrahim H, et al. The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric castleman's disease. Clin Exp Immunol 2008; 154: 399-405.
97. Sullivan RJ, Pantanowitz L, Casper C, et al. HIV/AIDS: epidemiology, pathophysiology, and treatment of kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric castleman disease. Clin Infect Dis 2008; 47: 1209-15.
98. Kumari P, Schechter GP, Saini N, et al. Successful treatment of human immunodeficiency virus-related castleman's disease with interferon-alpha. Clin Infect Dis 2000; 31: 602-4.
99. Nord JA, Karter D,. Low dose interferon-alpha therapy for HIV-associated multicentric castleman's disease. Int J STD AIDS 2003; 14: 61-2.
100. Aberg JA, Gallant JE, Ghanem KG, et al. Executive summary: primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis 2014; 58: 1-10.
101. Gill PS, Loureiro C, Bernstein-Singer M, et al. Clinical effect of glucocorticoids on kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 110: 937-40.
102. Murakami-Mori K, Mori S, Taga T, et al. Enhancement of gp130-mediated tyrosine phosphorylation of STAT3 and its DNA-binding activity in dexamethasone-treated AIDS-associated kaposi's sarcoma cells: selective synergy between dexamethasone and gp130-related growth factors in kaposi's sarcoma cell proliferation. J Immunol 1997; 158: 5518-26.
103. Volkow PF, Cornejo P, Zinser JW, et al. Life-threatening exacerbation of kaposi's sarcoma after prednisone treatment for immune reconstitution inflammatory syndrome. AIDS 2008; 22: 663-5.
104. Bower M, Powles T, Williams S, et al. Brief communication: Rituximab in HIV-associated multicentric castleman disease. Ann Intern Med 2007; 147: 836-9.
105. Neuville S, Agbalika F, Rabian C, et al. Failure of rituximab in human immunodeficiency virus-associated multicentric castleman disease. Am J Hematol 2005; 79: 337-9.
106. Buchler T, Dubash S, Lee V, et al. Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated castleman's disease with multiorgan failure: report of two cases. AIDS 2008; 22: 1685-7.
107. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with kaposi's sarcoma. J Clin Oncol 2005; 23: 5224-8.
108. Naresh KN, Trivedi P, Horncastle D, et al. CD20 expression in the HHV-8-infected lymphoid cells in multicentric castleman disease. Histopathology 2009; 55: 358-9.
109. Valencia ME, Moreno V, Martinez P, et al. Favorable outcome of castleman's disease treated with oral valganciclovir. Med Clin (Barc) 2005; 125: 399.
110. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric castleman disease. Blood 2005; 106: 2627-32.
111. van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for castleman's disease. J Clin Oncol 2010; 28: 3701-8.
112. Greene W, Kuhne K, Ye F, et al. Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res 2007; 133: 69-127.
113. French MA,. HIV/AIDS: immune reconstitution inflammatory syndrome: A reappraisal. Clin Infect Dis 2009; 48: 101-7.
114. Neuhaus J, Jacobs DR, Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201: 1788-95.